|
- Moderna says mRNA flu vaccine sailed through trial, beating . . .
An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week
- Moderna flu shot outperforms marketed vaccines in large late . . .
Moderna’s seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed shot targeting three or four strains of the virus, the company said Monday
- Moderna shines spotlight on new flu vaccine data | pharmaphorum
Moderna may be facing regulatory uncertainty in the US for its infectious disease vaccine pipeline, but at least its clinical data is hitting the right notes Today, the company revealed that its
- Modernas flu shot more effective for older adults - The Hill
Moderna Inc said Monday its experimental flu shot showed positive results in a late-stage trial In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent
- Modernas mRNA Flu Vaccine Achieves 90% Efficacy
In a landmark update that may redefine vaccine manufacturing strategies, Moderna announced on February 10, 2025, that its mRNA-based seasonal flu vaccine demonstrated a 90% efficacy rate in its Phase 3 trials—substantially outperforming traditional egg-based influenza vaccines
- Moderna’s Flu Vaccine Hits Goal, Paving Way for Combo Shot
Moderna Inc said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines
- Moderna Stock Is Climbing on Trial Data. A Flu-Covid Vaccine . . .
An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot But as scrutiny
|
|
|